| abstract |
The present invention is directed to the provision of a compound that is associated with CFTR as a causative agent in cystic fibrosis, which is caused by mutation of a cystic fibrosis transmembrane conductance regulator protein (CFTR), a type of chloride ion channel. Different chloride ion channels are opened, and they are effective compounds for treating cystic fibrosis without depending on CFTR.n n n The compound of the present invention is a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof, which is a calcium-dependent chloride channel (CaCC) through the agonistic effect of G protein coupled receptor 39 (GPR39) ) Open, and has strong chloride secretion. |